CN114767590B - 一种祛疤祛痘印美容液及其制备方法与应用 - Google Patents
一种祛疤祛痘印美容液及其制备方法与应用 Download PDFInfo
- Publication number
- CN114767590B CN114767590B CN202210420975.4A CN202210420975A CN114767590B CN 114767590 B CN114767590 B CN 114767590B CN 202210420975 A CN202210420975 A CN 202210420975A CN 114767590 B CN114767590 B CN 114767590B
- Authority
- CN
- China
- Prior art keywords
- acne
- scar
- extract
- percent
- cosmetic liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000002874 Acne Vulgaris Diseases 0.000 title claims abstract description 60
- 206010000496 acne Diseases 0.000 title claims abstract description 60
- 239000007788 liquid Substances 0.000 title claims abstract description 53
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 231100000241 scar Toxicity 0.000 claims abstract description 53
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 49
- 239000002537 cosmetic Substances 0.000 claims abstract description 44
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims abstract description 35
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims abstract description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 26
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract description 18
- 241001546929 Campsis grandiflora Species 0.000 claims abstract description 18
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims abstract description 18
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims abstract description 18
- 229960002216 methylparaben Drugs 0.000 claims abstract description 18
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims abstract description 18
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims abstract description 18
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 claims abstract description 17
- 229940059958 centella asiatica extract Drugs 0.000 claims abstract description 17
- 229920001577 copolymer Polymers 0.000 claims abstract description 17
- 229960002648 alanylglutamine Drugs 0.000 claims abstract description 16
- 108010044940 alanylglutamine Proteins 0.000 claims abstract description 16
- 229920002126 Acrylic acid copolymer Polymers 0.000 claims abstract description 15
- 229960005150 glycerol Drugs 0.000 claims abstract description 15
- 235000011187 glycerol Nutrition 0.000 claims abstract description 15
- 229960003415 propylparaben Drugs 0.000 claims abstract description 15
- 239000008367 deionised water Substances 0.000 claims abstract description 14
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 14
- 239000002994 raw material Substances 0.000 claims abstract description 12
- 230000019612 pigmentation Effects 0.000 claims abstract description 9
- 230000008439 repair process Effects 0.000 claims abstract description 5
- 238000003756 stirring Methods 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 15
- 206010020718 hyperplasia Diseases 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 230000002829 reductive effect Effects 0.000 claims description 5
- 206010011732 Cyst Diseases 0.000 claims description 3
- 208000031513 cyst Diseases 0.000 claims description 3
- 230000036573 scar formation Effects 0.000 claims description 3
- 230000008030 elimination Effects 0.000 claims description 2
- 238000003379 elimination reaction Methods 0.000 claims description 2
- UEFYOKRTWUGUPT-UHFFFAOYSA-N 2,3-dihydroxypropanoic acid;prop-2-enoic acid Chemical compound OC(=O)C=C.OCC(O)C(O)=O UEFYOKRTWUGUPT-UHFFFAOYSA-N 0.000 claims 1
- OWPUOLBODXJOKH-UHFFFAOYSA-N 2,3-dihydroxypropyl prop-2-enoate Chemical compound OCC(O)COC(=O)C=C OWPUOLBODXJOKH-UHFFFAOYSA-N 0.000 claims 1
- 229920006222 acrylic ester polymer Polymers 0.000 claims 1
- -1 propylene diglycerol acrylate Chemical compound 0.000 abstract description 12
- 206010039580 Scar Diseases 0.000 abstract description 6
- 206010061218 Inflammation Diseases 0.000 abstract description 4
- 230000004054 inflammatory process Effects 0.000 abstract description 3
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 23
- 210000003491 skin Anatomy 0.000 description 22
- 208000032544 Cicatrix Diseases 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- 230000037387 scars Effects 0.000 description 14
- QCYLIQBVLZBPNK-UHFFFAOYSA-N asiaticoside A Natural products O1C(C(=O)C(C)C)=CC(C)C(C2(C(OC(C)=O)CC34C5)C)C1CC2(C)C3CCC(C1(C)C)C45CCC1OC1OCC(O)C(O)C1O QCYLIQBVLZBPNK-UHFFFAOYSA-N 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 238000005096 rolling process Methods 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- WYQVAPGDARQUBT-FGWHUCSPSA-N Madecassol Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(CC[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O WYQVAPGDARQUBT-FGWHUCSPSA-N 0.000 description 8
- WYQVAPGDARQUBT-XCWYDTOWSA-N asiaticoside Natural products O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@@]4(C)[C@H]([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2 WYQVAPGDARQUBT-XCWYDTOWSA-N 0.000 description 8
- 229940022757 asiaticoside Drugs 0.000 description 8
- 238000010438 heat treatment Methods 0.000 description 6
- 239000002674 ointment Substances 0.000 description 6
- YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 230000001815 facial effect Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 4
- 230000006838 adverse reaction Effects 0.000 description 4
- 230000003796 beauty Effects 0.000 description 4
- 238000012372 quality testing Methods 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 229910052727 yttrium Inorganic materials 0.000 description 4
- VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 4
- 206010006784 Burning sensation Diseases 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- 238000001728 nano-filtration Methods 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000010257 thawing Methods 0.000 description 3
- 206010000503 Acne cystic Diseases 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000005416 organic matter Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 230000037072 sun protection Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 1
- 208000020154 Acnes Diseases 0.000 description 1
- 244000146462 Centella asiatica Species 0.000 description 1
- 235000004032 Centella asiatica Nutrition 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- BNMGUJRJUUDLHW-HCZMHFOYSA-N Madecassoside Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(C[C@@H](O)[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O BNMGUJRJUUDLHW-HCZMHFOYSA-N 0.000 description 1
- BNMGUJRJUUDLHW-HLUHVYOBSA-N Madecassoside Natural products C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5[C@H](O)C[C@@]34C)[C@@H]2[C@H]1C)C(=O)O[C@@H]6O[C@H](CO[C@@H]7O[C@H](CO)[C@@H](O[C@@H]8O[C@H](C)[C@H](O)[C@@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@@H](O)[C@H](O)[C@H]6O BNMGUJRJUUDLHW-HLUHVYOBSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 206010033372 Pain and discomfort Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- BAPJBEWLBFYGME-UHFFFAOYSA-N acrylic acid methyl ester Natural products COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- 239000002216 antistatic agent Substances 0.000 description 1
- JXSVIVRDWWRQRT-UYDOISQJSA-N asiatic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C JXSVIVRDWWRQRT-UYDOISQJSA-N 0.000 description 1
- 229940011658 asiatic acid Drugs 0.000 description 1
- LBGFKBYMNRAMFC-PYSQTNCISA-N asiatic acid Natural products C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@]2(C)[C@H]1C)C(=O)O LBGFKBYMNRAMFC-PYSQTNCISA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000002910 effect on acne Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- CLXOLTFMHAXJST-UHFFFAOYSA-N esculentic acid Natural products C12CC=C3C4CC(C)(C(O)=O)CCC4(C(O)=O)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(CO)C CLXOLTFMHAXJST-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- NWKFECICNXDNOQ-UHFFFAOYSA-N flavylium Chemical compound C1=CC=CC=C1C1=CC=C(C=CC=C2)C2=[O+]1 NWKFECICNXDNOQ-UHFFFAOYSA-N 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229930182489 iridoid glycoside Natural products 0.000 description 1
- 150000008145 iridoid glycosides Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- BUWCHLVSSFQLPN-UHFFFAOYSA-N madecassic acid Natural products CC1CCC2(CCC3(C)C(=CCC4C5(C)CC(O)C(O)C(C)(C5CCC34C)C(=O)O)C2C1C)C(=O)OC6OC(COC7OC(CO)C(OC8OC(C)C(O)C(O)C8O)C(O)C7O)C(O)C(O)C6O BUWCHLVSSFQLPN-UHFFFAOYSA-N 0.000 description 1
- PRAUVHZJPXOEIF-AOLYGAPISA-N madecassic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2[C@H](O)C[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C PRAUVHZJPXOEIF-AOLYGAPISA-N 0.000 description 1
- 229940011656 madecassic acid Drugs 0.000 description 1
- 229940090813 madecassoside Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 230000037075 skin appearance Effects 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A61K8/442—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof substituted by amido group(s)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/91—Injection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0061—Methods for using microneedles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Organic Chemistry (AREA)
- Birds (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属于美容制剂领域,具体涉及一种祛疤祛痘印美容液及其制备方法与应用。本发明所述祛疤祛痘印美容液,包括如下组分原料:积雪草提取物、金银花提取物、凌霄花提取物、丙氨酰谷氨酰胺、丙二甘油丙烯酸酯/丙烯酸共聚物、PVM/MA共聚物、甘油、羟苯甲酯、羟苯丙酯和去离子水。本发明提供的祛疤祛痘印美容液,能够有效抗炎、抑制痤疮疤痕形成与增生及软化已形成的陈旧性痘印,可修复红血丝及痘印色素沉着,同时具有皮肤锁水功能。
Description
技术领域
本发明涉及中药技术领域,具体涉及一种祛疤祛痘印美容液及其制备方法与应用。
背景技术
痤疮好发于面部及胸背部,是由于皮脂过度分泌及毛囊皮脂腺导管堵塞及毛痤疮丙酸杆菌而导致的毛周炎性皮肤病。除儿童外,人群中约有80%~90%的人患本病或曾经患过痤疮。炎性愈合往往残留疤痕,主要有色素沉着及凹陷性疤痕,国际上将凹陷性疤痕分为箱车型疤痕、滚动型疤痕、冰锥型疤痕。面部痤疮疤痕会对人的心理造成影响,很多人会因为痤疮疤痕而自卑,也有很多人失去了自由选择工作,选择婚姻的权利,正因如此,积极治疗痤疮疤痕显得尤为重要。
目前治疗痤疮疤痕药物中成药主要是积雪苷霜,广泛应用于临床。微针的滚针十分精细,在滚筒上布满了直径0.5mm-2mm的细针,当滚针在皮肤上滚动时,利用微小的针头多次穿刺皮肤,产生穿透真皮的微孔。创伤在真皮中引发伤口愈合和生长因子释放,可使胶原蛋白生成和在真皮上层沉积。微针治疗痤疮凹陷型疤痕疗效肯定,尤其是对箱车型疤痕及滚动型疤痕疗效确切,同时可刺激面部胶原再生,有一定全脸美容和提拉效果。临床上已有将积雪苷软膏结合微针导入应用于痤疮的报道,但膏体质地厚腻,舒适感差,并存在用药后面部易有红肿不适等反应。另微针在治疗后存在一段时期内皮肤干燥敏感甚至出现活动性干纹或局部色沉或肤色不均等副反应,且在操作过程中有疼痛不适等问题。
研发质地清爽、祛疤祛痘印疗效确切、可缓解微针治疗过程中的疼痛灼热感及减轻微针治疗副作用的美容液,具有非常重要的意义。
发明内容
为了克服现有技术中所存在的问题,本发明的目的在于提供一种祛疤祛痘印美容液及其制备方法与应用。
为了实现上述目的以及其他相关目的,本发明采用如下技术方案:
本发明的第一方面,提供一种祛疤祛痘印美容液,包括如下组分原料:积雪草提取物、金银花提取物、凌霄花提取物、丙氨酰谷氨酰胺、丙二甘油丙烯酸酯/丙烯酸共聚物、PVM/MA共聚物、甘油、羟苯甲酯、羟苯丙酯和去离子水。
在一些优选实施方式中,所述各组分原料之间的重量百分比为:积雪草提取物3.5%-20%、金银花提取物1.5%-10%、凌霄花提取物1.5%-10%、丙氨酰谷氨酰胺5.0%-20.0%、丙二甘油丙烯酸酯/丙烯酸共聚物15%-55%、PVM/MA共聚物1.0%-4.0%、甘油0.1%-1.0%、羟苯甲酯0.01%-0.15%、羟苯丙酯0.01%-0.05%、去离子水35%-55%。
在一些优选实施方式中,所述各组分原料之间的重量百分比为:积雪草提取物5-15%、金银花提取物2-5%、凌霄花提取物3-5%、丙氨酰谷氨酰胺8.0-15.0%、丙二甘油丙烯酸酯/丙烯酸共聚物20-30%、PVM/MA共聚物2.0-3.0%、甘油0.1-0.5%、羟苯甲酯0.02-0.1%、羟苯丙酯0.03-0.05%、去离子水40.0-50.0%。
在一些优选实施方式中,所述各组分原料之间的重量百分比为:积雪草提取物10%、金银花提取物3.5%、凌霄花提取物3.5%、丙氨酰谷氨酰胺10%、丙二甘油丙烯酸酯/丙烯酸共聚物25%、PVM/MA共聚物2.0%、甘油0.5%、羟苯甲酯0.05%、羟苯丙酯0.03%、去离子水45.42%。
本发明的第二方面,提供前述祛疤祛痘印美容液的制备方法,包括以下步骤:
S1、将积雪草提取物、金银花提取物、凌霄花提取物、丙氨酰谷氨酰胺搅拌,得到第一混合物;
S2、将丙二甘油丙烯酸酯/丙烯酸共聚物、PVM/MA共聚物、甘油、羟苯甲酯、羟苯丙酯和去离子水,搅拌,得到第二混合物;
S3、将步骤S1得到的第一混合物和步骤S2得到的第二混合物混合后搅拌,混合均匀,即得祛疤祛痘印美容液。
在一些优选实施方式中,步骤S1中所述搅拌速度为60~150rpm,搅拌时间为0.5~1h。
在一些优选实施方式中,步骤S2中所述搅拌速度为100~200rpm,搅拌时间为0.5~1h;
在一些优选实施方式中,步骤S3中所述搅拌速度为100~200rpm,搅拌时间为0.5~1h。
本发明的第三方面,提供前述祛疤祛痘印美容液在祛疤祛痘印方面的用途。
本发明的第四方面,提供前述祛疤祛痘印美容液在美容液在制备用于疤痕修复或痘印祛除的医疗或美容用产品中的用途。
本发明的第五方面,提供前述祛疤祛痘印美容液用于制备具有如下之任一功效的美容产品的用途:1)皮肤凹陷瘢痕修复;2)痘印色素沉着减轻;3)囊肿型痤疮消肿散结;4)抑制痤疮疤痕形成与增生。
本发明的第六方面,提供前述祛疤祛痘印美容液在制备微针基底液中的应用。
本发明的第七方面,提供一种祛疤祛痘印美容产品,包括前述的美容液。
本发明的第八方面,提供一种前述美容液的使用方法,包括以下步骤:
(a)使用前对患者面部进行消毒;
(b)选择0.5mm-1.0mm无菌滚针,在局部皮肤的各个方向进行交错、滚动3-5遍,边滚边涂抹前述美容液,直至局部皮肤出现肿胀结束治疗。
本发明提供的美容液配合微针治疗,利于液体有效成分导入,加强使用后效果,相比于直接涂敷,效果更佳。
与现有技术相比,本发明具有如下有益效果:
1、本发明所提供的祛疤祛痘印美容液,各组分间协同作用,可抑制瘢痕增生,减轻色素沉着,同时抗炎镇痛,起到清热止痛、保湿锁水的功效,适于作为微针治疗的基底液体。
2、本发明所提供的祛疤祛痘印美容液,对疤痕、痘印均具有显著的治疗效果,可显著改善患者的疤痕凹陷程度,使皮肤外观平整度得到改善,减轻痘印色素沉着,促进囊肿型痤疮消肿散结,抑制痤疮疤痕形成与增生,作为微针基底液使用能够减轻微针治疗的副作用,疗效优于积雪苷软膏,具有良好的临床应用价值。
附图说明
图1为典型病例1治疗前患处留档照片。
图2为典型病例1治疗后患处照片。
图3为典型病例2治疗前患处留档照片。
图4为典型病例2治疗后患处照片。
图5为典型病例3治疗前患处留档照片。
图6为典型病例3治疗后患处照片。
图7为典型病例3二次治疗前患处留档照片。
图8为典型病例3二次治疗后患处照片。
具体实施方式
本发明以积雪草提取液作为美容液的主要成分,其所含活性成分积雪苷具有清热利湿、解毒消痈的效果,可抑制瘢痕增生,减轻色素沉着,易于渗入皮肤且质地清爽;同时添加了金银花提取物与凌霄花提取物,二者协同消炎褪红,镇静舒缓,可有效缓解滚针后皮肤红肿敏感的问题;丙氨酰谷氨酰胺(力肽)中的寡肽-1、寡肽-3水解后生成L-谷氨酰胺,可促进人体主要角化细胞中LXR活性以及表皮脂质合成酶的激活,改善肌肤的水合作用,有利于肌肤抗衰老,同时又具有良好的锁水功能;聚乙烯醇缩甲醛/丙烯酸甲酯共聚物(PVM/MA共聚物)具有一定的润滑增稠性,与以上有效成分联合使用,除了增强美容液的保湿性之外,使本发明提供的美容液在作为微针治疗的基底液体时可有效缓解过程中的疼痛灼热感,减轻患者的痛苦。
丙二甘油丙烯酸酯/丙烯酸共聚物:市售化妆品原料。作增稠剂、黏度控制剂以及保湿剂使用,能够赋予美容液流动性和透明性,温和无刺激。
PVM/MA共聚物:市售化妆品原料。在化妆品中作抗静电剂、粘合剂和乳化稳定剂使用。
甘油:化学名为丙三醇,是一种无色、无嗅、味甘的粘稠液体,具有很强的吸水性,涂抹于皮肤上,可使皮肤湿润,不至于干裂。甘油吸收很快,对换季脱皮的肌肤,痘痘留疤的肌肤,敏感性肌肤等都是补水佳品,能够使皮肤保持柔软,富有弹性,不受尘埃、气候等损害而干燥。
羟苯甲酯:化学名为对羟基苯甲酸甲酯,也称尼泊金甲酯或羟苯甲酯,是一种有机物,化学式为C8H8O3,白色结晶粉末或无色结晶,具有易溶于醇,醚和丙酮,极微溶于水的性质,沸点270-280℃。主要用作有机合成、食品、化妆品、医药的杀菌防腐剂,也用作于饲料防腐剂。
羟苯丙酯:化学名为对羟基苯甲酸丙酯,也称尼泊金丙酯或对羟基安息香酸丙酯,是一种有机物,化学式为C10H12O3,白色结晶粉末,具有易溶于醇,醚和丙酮,微溶于水的性质,沸点133℃。主要用作有机合成、食品、化妆品、医药的杀菌防腐剂,也用作于饲料防腐剂。
在进一步描述本发明具体实施方式之前,应理解,本发明的保护范围不局限于下述特定的具体实施方案;还应当理解,本发明实施例中使用的术语是为了描述特定的具体实施方案,而不是为了限制本发明的保护范围。下列实施例中未注明具体条件的试验方法,通常按照常规条件,或者按照各制造商所建议的条件。
当实施例给出数值范围时,应理解,除非本发明另有说明,每个数值范围的两个端点以及两个端点之间任何一个数值均可选用。除非另外定义,本发明中使用的所有技术和科学术语与本技术领域技术人员通常理解的意义相同。除实施例中使用的具体方法、设备、材料外,根据本技术领域的技术人员对现有技术的掌握及本发明的记载,还可以使用与本发明实施例中所述的方法、设备、材料相似或等同的现有技术的任何方法、设备和材料来实现本发明。
除非另外说明,本发明中所公开的实验方法、检测方法、制备方法均采用本技术领域常规技术。
实施例1
一种祛疤祛痘印美容液,各组分原料之间的重量百分比为:积雪草提取物7.0%、金银花提取物3.0%、凌霄花提取物5.0%、丙氨酰谷氨酰胺8.0%、丙二甘油丙烯酸酯/丙烯酸共聚物20%、PVM/MA共聚物2.5%、甘油0.6%、羟苯甲酯0.10%、羟苯丙酯0.02%、去离子水53.78%。
实施例2
一种祛疤祛痘印美容液,各组分原料之间的重量百分比为:积雪草提取物10%、金银花提取物3.5%、凌霄花提取物3.5%、丙氨酰谷氨酰胺10%、丙二甘油丙烯酸酯/丙烯酸共聚物25%、PVM/MA共聚物2.0%、甘油0.5%、羟苯甲酯0.05%、羟苯丙酯0.03%、去离子水45.42%。
实施例3
一种祛疤祛痘印美容液,各组分原料之间的重量百分比为:积雪草提取物15%、金银花提取物6.0%、凌霄花提取物6.5%、丙氨酰谷氨酰胺5%、丙二甘油丙烯酸酯/丙烯酸共聚物15%、PVM/MA共聚物3.0%、甘油0.8%、羟苯甲酯0.15%、羟苯丙酯0.05%、去离子水48.5%。
临床应用
一、研究对象:上海交通大学医学院附属第九人民医院南院中医美容专科门诊患者,符合诊断标准和纳入标准。选取60例寻常痤疮疤痕患者。疤痕面积最小2cm,最大42cm,其中主要表现为冰锥型疤痕14例,滚动型疤痕27例,箱车型49例。治疗组30例,其中男2例,女28例,年龄最小21岁,最大35岁。治疗组30例,其中男1例,女性29例,年龄最小19岁,最大34岁,两组性别、年龄比较差异无统计学意义(P>0.05)。排除标准:患者近期有光敏药物服用史,有日光曝晒史,精神异常,妊娠女性、疤痕体质。
二、美容液配制
2.1主要组分生产厂家及产品号
积雪草提取液:上海钇琅化工科技有限公司,产品号YH-51512。固含量>3.5%,主要有药效成分为积雪草苷、羟基积雪草苷、积雪草酸和羟基积雪草酸。药理作用对金黄色葡萄球菌,溶血型链球菌、各种痢疾杆菌、伤寒杆菌均有抑制作用同时对瘢痕成纤维细胞活力有所影响。临床用于促进伤口愈合,抑制疤痕增生。提取流程:1.积雪草清洗,碾碎2.1,3丙二醇加热萃取3.过滤(300目过滤网)4.布滤5.纸滤6.加热浓缩7.质检8.冷冻9.解冻调整(调整PH等)10.纳滤11.灭菌12.防腐13.质检14.包装。
凌霄花提取液:上海钇琅化工科技有限公司,产品号YH-52868。固含量3.5%-10%,主要有药效成分为三萜类、黄酮类、花色素类、挥发油等。药理作用有改善血液循环、抑制血栓形成、镇痛、抗炎抗氧化作用。临床用于痤疮、激素依赖性皮炎等皮肤病。提取流程:1.凌霄花清洗,碾碎2.1,3丙二醇加热萃取3.过滤(300目过滤网)4.布滤5.纸滤6.加热浓缩7.质检8.冷冻9.解冻调整(调整PH等)10.纳滤11.灭菌12.防腐13.质检14.包装。
金银花提取液:上海钇琅化工科技有限公司,产品号YH-51120。固含量3.5%-10%,主要有药效成分为挥发油类、有机酸类、黄酮类、环烯醚萜苷类、三萜皂苷类等成分。药理作用清热解毒,凉散风热。临床用于:痈肿疗疮,喉痹,丹毒。提取流程:1.金银花清洗,碾碎2.1,3丙二醇加热萃取3.过滤(300目过滤网)4.布滤5.纸滤6.加热浓缩7.质检8.冷冻9.解冻调整(调整PH等)10.纳滤11.灭菌12.防腐13.质检14.包装。
力肽精华粉:上海钇琅化工科技有限公司。中文名称:丙氨酰谷氨酰胺,INCI名称ALANYL GLUTAMINE,CAS No.39537-23-0。本品为白色至淡黄色粉末,可溶于水,常温下性质稳定。其中,寡肽-1含量为35wt%,寡肽-3含量为20wt%,具有抗氧化、延缓皮肤衰老、促进组织修复和保湿锁水的功效。
2.2配制方法
按照下述步骤配制美容液:
步骤一、将上述积雪草提取液、金银花提取液、凌霄花提取液和力肽精华粉混合,以100rpm速度搅拌1h,得到第一混合物;
步骤二、将丙二甘油丙烯酸酯/丙烯酸共聚物、PVM/MA共聚物、甘油、羟苯甲酯、羟苯丙酯混合,加入去离子水,以130rpm搅拌1h,得到第二混合物;
步骤三、将步骤一得到的第一混合物和步骤二得到的第二混合物混合后以180rpm搅拌,混合均匀,即得祛疤祛痘印美容液。
上述方法配制得到的美容液中各组分的重量百分比为:积雪草提取物10%、金银花提取物3.5%、凌霄花提取物3.5%、丙氨酰谷氨酰胺10%、丙二甘油丙烯酸酯/丙烯酸共聚物25%、PVM/MA共聚物2.0%、甘油0.5%、羟苯甲酯0.05%、羟苯丙酯0.03%、去离子水45.42%。
三、术前准备
治疗前医护人员做好与患者的充分沟通交流,向患者介绍治疗方法、术中注意事项以及突发情况的预防方法,降低患者的心理压力,以取得患者的配合与理解。同时,术前对患者面部进行清洁并于同光源下照相留档。
四、治疗方法
治疗组面部消毒液进行消毒。微针治疗选择0.5mm-1.0mm无菌滚针,左手持上述配制好的美容液,在局部皮肤的各个方向进行交错、滚动3-5遍,边滚边涂抹美容液,直至局部皮肤出现肿胀为治疗终点。治疗后24小时内治疗部位禁止接触生水,并注意保湿和防晒。治疗1-6次,每个月2次。
对照组面部消毒液进行消毒。微针治疗选择0.5mm-1.0mm无菌滚针,在局部皮肤的各个方向进行交错、滚动3-5遍,直至局部皮肤出现肿胀为治疗终点。治疗结束后即时在疤痕处涂抹积雪苷软膏,涂抹治疗后24小时内治疗部位禁止接触生水,并注意保湿和防晒。治疗1-6次,每个月2次。
五、治疗结果
5.1疗效标准
(1)痊愈:患者疤痕凹陷修复程度达90%;
(2)显效:患者疤痕凹陷修复程度达60%上,外观平整,色泽不均明显减轻;
(3)有效:患者疤痕凹陷修复程度30%~59%,外观有一定改善,色泽不均明显减轻;
(4)无效:疤痕凹陷程度修复低于30%,外观无任何变化甚至加重。
总有效率=(痊愈例数+显效例数+有效例数)/总例数×100%。
5.2患者主观满意度调查。按照患者对治疗效果满意度和治疗体验分别进行的主观评价,将指标依次划十分满意、满意与不满意,满意率=(十分满意+满意)/例数×100%。
5.3对比两组不良反应发生情况。常见的不良反应有面部感染、皮肤过敏或敏感、色沉、其他(色沉、新发痤疮、红斑水肿)。
5.4统计学分析
采用SPSS 22.0对研究数据进行分析,计数资料采用百分率(%)表示,行χ2检验。P<0.05,提示差异有统计学意义。
5.5结果
5.5.1治疗效果如下表1所示:
表1两组患者疗效比较
注:χ2=7.341)P<0.05治疗组的有效率高于对照组。
由表1的统计结果可知,使用本发明提供的美容液配合滚针治疗疤痕凹陷及痘印的疗效优于积雪苷软膏,表明本发明提供的美容液具有良好的祛疤祛痘印效果。
5.5.2不良反应观察
表2两组患者不良反应比较
注:χ2=5.24P<0.05治疗组的不良反应发生率低于对照组。
由表2的统计结果可知,使用本发明提供的美容液配合滚针治疗疤痕凹陷及痘印的不良反应发生率低于积雪苷软膏,表明本发明提供的美容液能够减轻微针治疗的副作用。
5.5.3满意度调查
治疗组患者对治疗效果的满意度为95.53%,明显高于对照组76.47%,差异有统计学意义(P<0.05)。治疗组患者对治疗体验的满意度为93.33%,明显高于对照组66.67%,差异有统计学意义(P<0.05)。其中,治疗体验满意度调查过程中采用VRS法让治疗组患者和对照组患者分别对治疗过程中的疼痛灼热感进行评估,治疗组患者评估结果为19例轻微疼痛和11例中度疼痛,对照组患者为5例轻微疼痛、18例中度疼痛和7例剧烈疼痛。
典型病例
病例1:陈某某,女,30岁,上海医院职工。因反复痤疮三个月,留有色素疤痕1月余就诊,2020年11月来我院治疗,图1为治疗前留档照片;采用本发明祛疤祛痘印美容液配合滚针治疗,每周一次,共治疗4次。图2为治疗后留档照片,可以明显看到面颊部位的数枚痘印颜色明显变淡,部分消失,面部皮肤较前白皙紧致。
病例2:孙某某,女,27岁,上海在职白领。有痤疮史多年,曾自行外用激素类药物后,继发皮肤粗糙伴色素沉着。2020年11月来我院治疗,图3为治疗前留档照片;采用本发明祛疤祛痘印美容液配合滚针治疗,每两周一次,共治疗4次。图4为治疗后留档照片,可以明显看到两颊痘坑变浅,痘印色素沉着变淡,皮肤毛孔缩小,较治疗前细腻白皙。
病例3:金某某,男,19岁,上海在校学生。痤疮史2年,局部留有明显凹陷性痘坑,下颌处有囊肿性痤疮,2020年12月来我院治疗,图5为治疗前留档照片;采用本发明祛疤祛痘印美容液配合滚针治疗,每周一次,治疗四次后,图6为治疗后留档照片,可以明显看到,囊肿型痤疮明显缩小消褪,痘印消失,三个月后,因患者痤疮又有新发数枚,留有痘印,应患者主动要求,又行2次治疗,图7,图8为两次治疗后分别留档照片,可以明显看到痘印消褪,皮肤较之前光滑、紧致。
以上所述,仅为本发明的较佳实施例,并非对本发明任何形式上和实质上的限制,应当指出,对于本技术领域的普通技术人员,在不脱离本发明方法的前提下,还将可以做出若干改进和补充,这些改进和补充也应视为本发明的保护范围。凡熟悉本专业的技术人员,在不脱离本发明的精神和范围的情况下,当可利用以上所揭示的技术内容而做出的些许更动、修饰与演变的等同变化,均为本发明的等效实施例;同时,凡依据本发明的实质技术对上述实施例所作的任何等同变化的更动、修饰与演变,均仍属于本发明的技术方案的范围内。
Claims (5)
1.一种祛疤祛痘印美容液在制备微针基底液中的应用,所述美容液包括如下重量百分比的组分原料:积雪草提取物3.5%-20%、金银花提取物1.5%-10%、凌霄花提取物1.5%-10%、丙氨酰谷氨酰胺5.0%-20.0%、甘油丙烯酸酯/丙烯酸共聚物15%-55%、PVM/MA共聚物1.0%-4.0%、甘油0.1%-1.0%、羟苯甲酯0.01%-0.15%、羟苯丙酯0.01%-0.05%、去离子水35%-55%。
2.如权利要求1所述应用,其特征在于,所述美容液各组分原料之间的重量百分比为:积雪草提取物10%、金银花提取物3.5%、凌霄花提取物3.5%、丙氨酰谷氨酰胺10%、甘油丙烯酸酯/丙烯酸共聚物25%、PVM/MA共聚物2.0%、甘油0.5%、羟苯甲酯0.05%、羟苯丙酯0.03%、去离子水45.42%。
3.如权利要求1~2任一所述的应用,其特征在于,所述美容液的制备方法包括以下步骤:
S1、将积雪草提取物、金银花提取物、凌霄花提取物、丙氨酰谷氨酰胺搅拌,得到第一混合物;
S2、将甘油丙烯酸酯/丙烯酸共聚物、PVM/MA共聚物、甘油、羟苯甲酯、羟苯丙酯和去离子水,搅拌,得到第二混合物;
S3、将步骤S1得到的第一混合物和步骤S2得到的第二混合物混合后搅拌,混合均匀,即得祛疤祛痘印美容液。
4.如权利要求3所述的应用,其特征在于,还包括以下特征中的一项或几项:
(1)步骤S1中所述搅拌速度为60~150 rpm,搅拌时间为0.5~1 h;
(2)步骤S2中所述搅拌速度为100~200 rpm,搅拌时间为0.5~1 h;
(3)步骤S3中所述搅拌速度为100~200 rpm,搅拌时间为0.5~1 h。
5.如权利要求1~2任一项所述的应用,所述美容液具有如下功效:1)皮肤凹陷瘢痕修复;2)痘印色素沉着减轻;3)囊肿型痤疮消肿散结;4)抑制痤疮疤痕形成与增生。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210420975.4A CN114767590B (zh) | 2022-04-20 | 2022-04-20 | 一种祛疤祛痘印美容液及其制备方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210420975.4A CN114767590B (zh) | 2022-04-20 | 2022-04-20 | 一种祛疤祛痘印美容液及其制备方法与应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114767590A CN114767590A (zh) | 2022-07-22 |
CN114767590B true CN114767590B (zh) | 2024-03-15 |
Family
ID=82431318
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210420975.4A Active CN114767590B (zh) | 2022-04-20 | 2022-04-20 | 一种祛疤祛痘印美容液及其制备方法与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114767590B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103002903A (zh) * | 2010-06-28 | 2013-03-27 | Ade治疗公司 | 瘢痕疙瘩治疗法 |
CN109646356A (zh) * | 2019-01-30 | 2019-04-19 | 邯郸市丛台区本草汉方贸易有限公司 | 中药组合物、其用途及面膜 |
CN111419757A (zh) * | 2020-04-30 | 2020-07-17 | 南京苗邦美业企业管理有限公司 | 一种草本护肤修护精华液 |
-
2022
- 2022-04-20 CN CN202210420975.4A patent/CN114767590B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103002903A (zh) * | 2010-06-28 | 2013-03-27 | Ade治疗公司 | 瘢痕疙瘩治疗法 |
CN109646356A (zh) * | 2019-01-30 | 2019-04-19 | 邯郸市丛台区本草汉方贸易有限公司 | 中药组合物、其用途及面膜 |
CN111419757A (zh) * | 2020-04-30 | 2020-07-17 | 南京苗邦美业企业管理有限公司 | 一种草本护肤修护精华液 |
Also Published As
Publication number | Publication date |
---|---|
CN114767590A (zh) | 2022-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109157451B (zh) | 一种祛痘洁面乳 | |
CN107375032B (zh) | 一种修复皮肤屏障的组合物及制备方法 | |
EP0738516A1 (en) | External preparation for skin protection | |
CN109260075B (zh) | 一种祛痘调理水 | |
CN108653129B (zh) | 一种包含天然植物抗敏组合物的皮肤敷料 | |
US7655255B2 (en) | Topical composition for transdermal administration | |
CN111588815B (zh) | 一种外用祛痘中药组合物及其应用与含有该组合物的祛痘平衡精华 | |
US20060222689A1 (en) | Skin care compositions and methods | |
CN111773272A (zh) | 一种治疗痤疮的外用复合配方及其制备方法 | |
KR102141574B1 (ko) | 두피케어 화장료 조성물 및 그 제조방법 | |
CN111671692A (zh) | 一种祛痘组合物及其制备方法与应用 | |
CN111529450A (zh) | 深层补水修复组合物,其护肤品及制备方法 | |
CN112516066B (zh) | 一种控油组合物及其在化妆品中的应用 | |
US20020176876A1 (en) | Topical therapeutic skin care system | |
CN102335231B (zh) | 一种用于治疗黄褐斑的中药润肤霜及其制备方法和应用 | |
CN114767590B (zh) | 一种祛疤祛痘印美容液及其制备方法与应用 | |
CN108721154B (zh) | 一种用于皮肤保湿和屏障修复的护肤品及其制备方法 | |
CN106511153B (zh) | 一种具有祛痘功效的纳米组合物及其化妆品或护肤品 | |
CN109568230A (zh) | 一种保湿美白的抗衰老的中药化妆品 | |
EP1752132A2 (en) | Skin cosmetic compositions | |
CN113925825A (zh) | 一种面部精华液及其制备方法 | |
CN113081933A (zh) | 祛痘组合物及其制备方法与应用 | |
CN112807238A (zh) | 一种皮肤抗炎舒缓修护凝胶及其制备方法 | |
KR102012019B1 (ko) | 튼살 예방 및 치료용 패치 | |
CN112057388A (zh) | 一种用于妊娠纹修复的乳霜及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |